Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

Get full text

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma by Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio

Get full text

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study by Clara Mayo de las Casas, Eloisa Jantus-Lewintre, Sebastian Ortiz Reina, Ana Drozdowskyj, Pablo Cerezuela-Fuentes, Jose Luis Manzano, Pablo Ayala de Miguel, Ana Arance Fernandez, Miguel Angel Berciano-Guerrero, Almudena Garcia-Castaño, Teresa Puertolas, Guillermo Crespo, Maria Quindos-Varela, Juan Francisco Rodriguez-Moreno, Alfonso Berrocal, Eva Muñoz-Couselo, Enrique Espinosa, Joselyn Valarezo, Susana Muñoz, Silvia Calabuig-Fariñas, Miguel Angel Molina, Rafael Rosell, Joan Anton Puig-Butille, Maria Gonzalez-Cao

Get full text